Eloxx Pharmaceuticals Inc (OTCPK:ELOX)
$ 0.8 0 (0%) Market Cap: 2.52 Mil Enterprise Value: 3.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q4 2019 Eloxx Pharmaceuticals Inc Earnings Call Transcript

Mar 05, 2020 / 09:30PM GMT
Release Date Price: $138 (-9.92%)
Operator

Good afternoon, everyone, and welcome to Eloxx Pharmaceuticals' Fourth Quarter and Full Year 2019 Earnings Webcast and Conference Call. Today's call is being recorded.

At this time, I would like to turn the call over to Barbara Ryan, Eloxx' Investor Relations. Please begin.

Barbara Ryan
Eloxx Pharmaceuticals, Inc. - IR Officer

Thank you, Gigi. Welcome and thank you for joining us this afternoon for a review of Eloxx Pharmaceuticals' fourth quarter and full year 2019 financial results and business update. Joining me this afternoon are Dr. Greg Williams, Chief Executive Officer; Neil Belloff, Chief Operating Officer and General Counsel; Tom -- Dr. Tom Haverty, our Chief Medical Officer; Dr. Matthew Goddeeris, our VP of Research; and Stephen MacDonald, our Vice President of Finance and Accounting.

Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot